Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
The DOI matches its Crossref record.
Abstract
OBJECTIVE: Pharmacokinetics, safety, and tolerability of GSK1265744 (744) and rilpivirine (RPV) (TMC278) were assessed after repeat dosing of long-acting (LA) injectable formulations in healthy subjects. METHODS: Subjects received a 14-day lead-in of oral 744 (30 mg/d) to assess safety and tolerability before injectable administration. Subjects were randomized into 4 cohorts: 800 mg of 744 LA intramuscularly (IM) followed by 3 monthly doses of (1) 200 mg subcutaneously, (2) 200 mg IM, (3) 400 mg IM, or (4) a second injection of 800 mg IM after 12 weeks. Cohorts 2 and 3 also received IM doses of RPV LA at months 3 (1200 mg) and 4 (900 or 600 mg). Pharmacokinetics and safety were assessed throughout the trial. RESULTS: Forty-seven subjects enrolled; 40 received ≥1 LA injection with 37 completing all planned injections. Seven subjects discontinued 744 oral (non-drug-related, n = 6; dizziness, n = 1). The 744 LA and RPV LA injections were generally well tolerated, with grade 1 injection site reactions most commonly reported. Three subjects discontinued during injection phase (consent withdrawn, n = 2; self-limited rash, n = 1). There were no grade 3 or 4 adverse events and no clinically significant trends in laboratory abnormalities, electrocardiograms, or vital signs. All dose cohorts achieved therapeutically relevant plasma concentrations of each drug within 3 days with prolonged exposure over the dosing interval. Plasma concentrations of 744 exceeded the protein-adjusted IC90 and RPV plasma concentrations and were comparable to steady-state oral RPV 25 mg/d. CONCLUSIONS: These data support the potential application of dual-therapy 744 LA and RPV LA for treatment of HIV-1 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Margolis, D. A., Gonzalez-Garcia, J., Stellbrink, H.-J., Eron, J. J., Yazdanpanah, Y., Podzamczer, D., Lutz, T., Angel, J. B., Richmond, G. J., Clotet, B., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31917-7 · Cited by 499
Self-citationEmerging role of nanosuspensions in drug delivery systems
Jacob, S., Nair, A. B., & Shah, J. (2020) · Biomaterials Research · doi:10.1186/s40824-020-0184-8 · Cited by 415
Adejumo, O. A., Malee, K. M., Ryscavage, P., Hunter, S. J., & Taiwo, B. O. (2015) · Journal of the International AIDS Society · doi:10.7448/ias.18.1.20049 · Cited by 263
Development of an oral once-weekly drug delivery system for HIV antiretroviral therapy
Kirtane, A. R., Abouzid, O., Minahan, D., Bensel, T., Hill, A. L., Selinger, C., Bershteyn, A., Craig, M., Mo, S. S., Mazdiyasni, H., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02294-6 · Cited by 227
Formulation and pharmacology of long-acting cabotegravir
Trezza, C., Ford, S. L., Spreen, W., Pan, R., & Piscitelli, S. (2015) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000168 · Cited by 179
Self-citation
Metadata
- Authors
- Spreen, W., Williams, P., Margolis, D., Ford, S. L., Crauwels, H., Lou, Y., Gould, E., Stevens, M., & Piscitelli, S.
- Venue
- JAIDS Journal of Acquired Immune Deficiency Syndromes
- Published
- 2014-12-15
- Volume
- 67
- Issue
- 5
- Pages
- 487-492
- ISSN
- 1525-4135 (ISSN-L)
- OpenAlex
- W2024823439
- Cited by
- 112
- References
- 0
- FWCI
- 8.65
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults. https://app.cochat.ai/papers/10.1097/qai.0000000000000365
- The paper
- Spreen, W., Williams, P., Margolis, D., Ford, S. L., Crauwels, H., Lou, Y., Gould, E., Stevens, M., & Piscitelli, S. (2014). Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults. JAIDS Journal of Acquired Immune Deficiency Syndromes. https://doi.org/10.1097/qai.0000000000000365
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.